Executive Director, PM Portfolio Lead for Oncology at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, OncologyIndustries

Requirements

Line management leadership, coaching, and development experience for large teams including Director-level members
Expertise in Program Management (PM) as subject matter experts (SMEs) within Oncology therapeutic area
Ability to oversee PMs assigned to asset programs (GPT) and early/late development projects of varying scope and complexity
Strong business partnership skills with Global Franchise Leads (GPLs) and Therapeutic Area Heads
Knowledge of PM/GPL partnership, asset/portfolio inflection points, risk management, disease area strategies, and GPT Operating Model
Capability to hold team accountable for Program/Project Management responsibilities (e.g., ADP execution, integrated schedules, critical path assessment, scenario planning, timeline visualizations)
Experience in leading risk management at asset/indication level and ensuring practices across sub-teams
Proficiency in governance readiness, PM systems/processes, budget/resource oversight, and data quality standards
Strategic oversight of development inflection points and ability to identify acceleration opportunities
Coaching skills to develop direct reports within PM career ladder and enterprise/portfolio perspective

Responsibilities

Manage a large team including one or more Director-level team members with direct reports
Provide line management leadership, coaching, and development to grow PM team as SMEs
Maintain oversight for PMs on asset programs (GPT) and early/late development projects
Prioritize personnel line management and execution of Oncology therapeutic area portfolio
Serve as key business partner to Global Franchise Leads and Therapeutic Area Heads, including PM/GPL partnership, assignments, performance oversight, inflection points, risk escalation, disease strategies, and GPT Operating Model evolution
Hold team accountable for delivering Program/Project Management responsibilities (e.g., ADP/indication plans, integrated schedules, critical path, scenario planning, timeline visualizations)
Directly lead asset/indication risk management and ensure delivery by GPT sub-teams/execution teams
Provide leadership for team governance readiness
Oversee GPT budget and resource health
Ensure team data/outputs meet PPM data quality expectations
Maintain close oversight of key development inflection points
Act as thought partner to challenge ADPs and identify acceleration opportunities
Develop and coach direct reports to advance in PM career ladder and understand enterprise/portfolio insights

Skills

Program Management

Portfolio Management

Line Management

Leadership

Coaching

Oncology

Therapeutic Area Management

Global Franchise Management

Team Development

Subject Matter Expertise

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free